Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BPTH / Bio-Path Holdings, Inc. FORM S-8

2018-02-20 sec.gov
    As filed with the Securities and Exchange Commission on February 20, 2018 Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933       BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)       Delaware   87-0652870 (State or other jurisdiction of   (I.R.S. (39-0)

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-02-09 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): February 5, 2018   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

ECA2018-26 - Reverse Split and CUSIP Number Change for Bio-Path Holdings, Inc. (BPTH)

2018-02-09 nasdaqtrader
Bio-Path Holdings, Inc. (BPTH) will effect a one-for-ten (1-10) reverse split of its common stock. The reverse stock split will become effective on Friday, February 9, 2018. In conjunction with the reverse split, the CUSIP number will change to 09057N201. (39-0)

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-02-05 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     Date of report (Date of earliest event reported): February 1, 2018   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2018-01-02 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): December 29, 2017   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

BPTH / Bio-Path Holdings, Inc. ER

2017-12-31 sec.gov
November 22, 2017 Peter H. Nielsen President and Chief Executive Officer Bio-Path Holdings, Inc. 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 77401 Bio-Path Holdings, Inc. Registration Statement on Form S-3 Filed November 16, 2017 File No. 333-221610 Re: Dear Mr. Nielsen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

BPTH / Bio-Path Holdings, Inc. ESP

2017-12-31 sec.gov
       November 27, 2017   VIA EDGAR   Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Bio-Path Holdings, Inc. Registration Statement on Form S-3 File No. 333-221610   Ladies and Gentlemen:   In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2017-12-27 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): December 21, 2017   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

2017-12-15 accesswire
Bio-Path Holdings, Inc. (Bio-Path) is a clinical-stage biotechnology company that focuses on developing nucleic acid cancer therapeutics using its proprietary nanoparticle RNAi antisense technology called DNAbilize®. This technology safely distributes nucleic acid-based drugs systemically throughout the body via intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001), is in Phase 2 clinical studies for the treatment of acute and chronic myeloid leukemia (AML and CML), and preclinical studies for solid tumors. (39-0)

BPTH / Bio-Path Holdings, Inc. FORM S-3

2017-11-16 sec.gov
       As filed with the Securities and Exchange Commission on November 16, 2017 Registration No. 333-   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM S-3   REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933       BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 77401 (832) 742-1357 87-0652870 (State or other jurisdiction of incorporation or organization) (Address

Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant Pharmaceuticals International, Inc. (NYSE: VRX) ("Valeant"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=VRX. The Company announced on November 10, 2017, that it has completed the sale of the Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L. (270-1)

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good morning, ladies and gentlemen and welcome to the Bio-Path Holdings Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we’ll open up the call to your questions. (54-0)

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2017-11-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549    FORM 8-K    CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934    Date of report (Date of earliest event reported):  November 9, 2017   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)     Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation)   (Commission File Number) (IRS Employer Identification No.

BPTH / Bio-Path Holdings, Inc. FORM 10-Q (Quarterly Report)

2017-11-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q   (Mark One)   x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended September 30, 2017   Or   ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from ________________________   Commission file number: 001-36333   Bio-Path Holdings, Inc.

BPTH / Bio-Path Holdings, Inc. FORM 8-K (Current Report)

2017-11-07 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     Date of report (Date of earliest event reported): November 6, 2017   BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter)   Delaware 001-36333 87-0652870 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.


CUSIP: 09057N102